Potential effectiveness and safety of olanzapine in refractory panic disorder

Depression and Anxiety

Volumn 21, Issue 1, 2005, Pages 33-40

  Hollifield, Michael ^a,c   Thompson, Peter M ^b   Ruiz, James E ^a   Uhlenhuth, E H ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c University of Louisville School of Medicine   (United States)

Author keywords

Anxiety; Clinical trial; Olanzapine; Panic disorder; Psychopharmacology

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CLOZAPINE; NORADRENALIN UPTAKE INHIBITOR; OLANZAPINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AKATHISIA; ANTICIPATION; ARTICLE; BEHAVIOR THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HUMAN; MALE; OPEN STUDY; OUTCOMES RESEARCH; PANIC; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; WEIGHT GAIN;

ADULT; BENZODIAZEPINES; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; PANIC DISORDER; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX;

EID: 18144396514     PISSN: 10914269     EISSN: None     Source Type: Journal    
DOI: 10.1002/da.20050     Document Type: Article

References (54)

1. Aaronson NK, Acquadro C, Alonso J, Apolone G, Bucquet D. Bullinger M, Bungay K, Fukuhara S, Gandek B, Keller S. 1992. International quality of life assessment (IQOLA) project. Qual Life Res 1:349-351.
2. Andersch S, Rosenberg NK, Kullingsjo H, Ottosson JO, Bech P, Brunn-Hansen J, Hanson L, Lorentzen K, Mellergard M, Rasmussen S, Rosenberg R. 1991. Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder. A Scandinavian multicenter study. Acta Psychiatr Scand Suppl 365:18-27.
3. Ballenger JC, Burrows GD, Dupont RL Jr, Lesser IM, Noyes R Jr, Pecknold JC, Rifkin A, Swinson RP. 1988. Alprazolam in panic disorder and agoraphobia: Results from a multicenter trial. 1. Efficacy in short-term treatment. Arch Gen Psychiatry 45: 413-422.
4. Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Baldwin DS, den Boer JA, Kasper S, Shear MK. 1998. Consensus statement on panic disorder from the International Consensus Group on depression and anxiety. J Clin Psychiatry 59(Suppl):47-54.
5. Barlow DH, Gorman JM, Shear MK, Woods SW. 2000. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. JAMA 283:2529-2536.
6. Barnes TRE. 1989. A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676.
7. Bever KA, Perry PJ. 1998. Olanzapine: a serotonin-dopamine receptor antagonist for antipsychotic therapy. Am J Health Syst Pharm 55:1003-1016.
8. Bressan RA, Monteiro VBM, Dias CC. 2000. Panic disorder associated with clozapine [letter]. Am J Psychiatry 157:2056.
9. Butterfield MI, Becker ME, Connor KM, Sutherland S, Churchill LE, Davidson JRT. 2001. Olanzapine in the treatment of posttraumatic stress disorder: A pilot study. Int Clin Psychopharmacol 16:197-203.
10. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. 1999. Olanzapine: Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 37:177-193.
11. Clark DM, Salkovskis PM, Hackmann A, Middleton H, Anastasiades P, Gelder M. 1994. A comparison of cognitive therapy, applied relaxation and imipramine in the treatment of panic disorder. Br J Psychiatry 164:759-769.
12. Cowley DS, Ha EH, Roy-Byrne PP. 1997. Determinants of pharmacologic treatment failure in panic disorder. J Clin Psychiatry 58:555-561.
13. Cross-National Collaborative Panic Study, Second Phase Investigators. 1992. Drug treatment of panic disorder. Comparative efficacy of alprazolam, imipramine, and placebo. Br J Psychiatry 160: 191-202.
14. Dick CL, Bland RC, Newman SC. 1994. Epidemiology of psychiatric disorders in Edmonton. Panic disorder. Acta Psychiatr Scand Suppl 376:45-53.
15. Eaton WW, Kessler RC, Wittchen HU, Magee WJI. 1994. Panic and panic disorder in the United States. Am J Psychiatry 151: 413-420.
16. Eli Lilly and Company. Zyprexa home page. Available online at http://www.zyprexa.com. Accession date: June 2003.
17. Etxebeste M, Aragues E, Malo P, Pacheco L. 2000. Olanzapine and panic attacks [letter]. Am J Psychiatry 157:659-660.
18. Faravelli C, Guerrini Degl'Innocenti B, Giardinelli L. 1989. Epidemiology of anxiety disorders in Florence. Acta Psychiatr Scand 79:308-312.
19. Guy W. 1976. ECDEU assessment manual for psychopharmacology. Rockville, MD: US Department of Health, Education and Welfare. 603 p.
20. Hollander E, Cohen LJ. 1994. The assessment and treatment of refractory anxiety. J Clin Psychiatry 55(Suppl):27-31.
21. Hollifield M, Katon W, Skipper B, Chapman T, Ballenger JC, Mannuzza S, Fyer AJ. 1997. Panic disorder and quality of life: Variables predictive of functional impairment. Am J Psychiatry 154:766-772.
22. Hollifield M, Katon W, Spain D, Pule L. 1990. Anxiety and depression in a village in Lesotho, Africa: A comparison with the United States. Br J Psychiatry 156:343-350.
23. Inoue T, Tsuchiya K, Koyama T. 1996. Effects of typical and atypical antipsychotic drugs on freezing behavior induced by conditioned fear. Pharmacol Biochem Behav 55:195-201.
24. Joyce PR, Bushnell JA, Oakley-Browne MA, Wells JE, Hornblow AR. 1989. The epidemiology of panic symptomatology and agoraphobic avoidance. Compr Psychiatry 30:303-312.
25. Kaplan M. 2000. Atypical antipsychotics for treatment of mixed depression and anxiety [letter]. J Clin Psychiatry 61:388-399.
26. Katon W. 1986. Panic disorder: epidemiology, diagnosis, and treatment in primary care. J Clin Psychiatry 47(Suppl):21-30.
27. Khaldi S, Kornreich C, Dan B, Pelc I. 2003. Usefulness of olanzapine in refractory panic attacks. J Clin Psychopharmacol 23:100-101.
28. Klerman GL, Weissman MM, Ouellette R, Johnson J, Greenwald S. 1991. Panic attacks in the community. Social morbidity and health care utilization. JAMA 265:742-746.
29. Klieser E, Wurthmann C, Czekalla J, Landefeld H, Lemmer W, Schulte T. 2000. Exploratory pilot study with olanzapine in generalized anxiety disorder (GAD) showed anxiolytic treatment with low dosages of the atypical antipsychotic. Eur Neuropsychopharmacol 10:s344.
30. Koller EA, Doraiswamy PM. 2002. Olanzapine-associated diabetes mellitus. Pharmacotherapy 22:841-852.
31. Lecrubier Y, Judge R. 1997. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand 95:153-160.
32. Leon AC, Shear MK, Portera L, Klerman GL. 1992. Assessing impairment in patients with panic disorder: The Sheehan Disability Scale. Soc Psychiatry Psychiatr Epidemiol 27:78-82.
33. Mandalos GE, Szarek BL. 1999. New-onset panic attacks in a patient treated with olanzapine. J Clin Pharmacol 19:191.
34. Mathew SJ, Coplan JD, Gorman JM. 2001. Management of treatment-refractory panic disorder. Psychopharmacol Bull 35:97-110.
35. McHorney CA, Ware JE, Raczek AE. 1993. The MOS 36-item Short Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 31:247-263.
36. Myers JK, Weissman MM, Tischler GL, Holzer CE 3rd, Leaf PJ, Orvaschel H, Anthony JC, Boyd JH, Burke JD Jr, Kramer M, Stoltzman R. 1984. Six-month prevalence of psychiatric disorders in three communities 1980 to 1982. Arch Gen Psychiatry 41: 959-967.
37. National Institute of Mental Health. 1985. Special feature: rating scales and assessment instruments for use in pediatric psychopharmacology research. Psychopharmacol Bull 21:713-1125.
38. Noyes R Jr, Burrows GD, Reich JH, Judd FK, Garvey MJ, Norman TR, Cook BL, Marriott P. 1996. Diazepam versus alprazolam for the treatment of panic disorder. J Clin Psychiatry 57:349-355.
39. Oehrberg S, Christiansen PE, Behnke K, Borup AL, Severin B, Soegaard J, Calberg H, Judge R, Ohrstrom JK, Manniche PM. 1995. Paroxetine in the treatment of panic disorder. A randomized, double-blind, placebo-controlled study. Br J Psychiatry 167:374-379.
40. Petty F, Brannan S, Casada J, Davis LL, Gajewski V, Kramer GL, Stone RC, Teten AL, Worchel J, Young KA. 2001. Olanzapine treatment for post-traumatic stress disorder: An open-label study. Int Clin Psychopharmacol 16:331-337.
41. Pollack MH, Otto MW, Kaspi SP, Hammerness PG, Rosenbaum JF. 1974. Cognitive behavior therapy for treatment-refractory panic disorder. J Clin Psychiatry 55:200-205.
42. Rapaport MH, Wolkow R, Rubin A, Hackett E, Pollack M, Ota KY. 2001. Sertraline treatment of panic disorder: Results of a long-term study. Acta Psychiatr Scand 104:289-298.
43. Schweizer E, Patterson W, Rickels K, Rosenthal M. 1993. Doubleblind, placebo-controlled study of a once-a-day, sustained-release preparation of alprazolam for the treatment of panic disorder. Am J Psychiatry 150:1210-1215.
44. Sheehan DV. 1983. The anxiety disease. New York: Scribner. 206 p.
45. Sheikh JI, Londborg P, Clary CM, Fayyad R. 2000. The efficacy of sertraline in panic disorder: Combined results from two fixed-dose studies. Int Clin Psychopharmacol 15:335-342.
46. Simon NM, Safrens SA, Otto MW, Sharma SS, Lanka GD, Pollack MH. 2002. Outcome pharmacotherapy in a naturalistic study of panic disorder. J Affect Disord 69:201-208.
47. Simpson GM, Angus JWS. 1970. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 221:11-19.
48. Spitzer RL, Williams JBW, Gibbon M, First MB. 1992. The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description. Arch Gen Psychiatry 49:624-629.
49. Tesar GE, Rosenbaum JF, Pollack MH, Otto MW, Sachs GS, Herman JB, Cohen LS, Spier SA. 1991. Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder. J Clin Psychiatry 52:69-76.
50. Von Korff MR, Eaton WW, Keyl PM. 1985. The epidemiology of panic attacks and panic disorder. Results of three community surveys. Am J Epidemiol 122:970-981.
51. Ware JE, Snow KK, Kosinski M. 1993. SF-36 health survey: manual and interpretation guide. Boston, MA: New England Health Center, The Health Institute.
52. Weissman MM, Klerman GL, Markowitz JS, Ouellette R. 1989. Suicidal ideation and attempts in panic disorder and attacks. N Engl J Med 321:1209-1214.
53. Weissman MM, Bland RC, Canino GJ, Faravelli C, Greenwald S, Hwu HG, Joyce PR, Karam EG, Lee CK, Lellouch J, Lepine JP, Newman SC, Oakley-Browne MA, Rubio-Stipec M, Wells JE, Wickramaratne PJ, Wittchen HU, Yeh EK. 1997. The cross-national epidemiology of panic disorder. Arch Gen Psychiatry 54:305-309.
54. Zaubler TS, Katon W. 1996. Panic disorder and medical comorbidity: A review of the medical and psychiatric literature. Bull Menninger Clin 60(Suppl):A12-A38.